Safety and Efficacy Study of ENB-0040 in Juvenile Patients With Hypophosphatasia (HPP)

Study Identifier:
ENB-004-09
ClinicalTrials.gov Identifier:
NCT00894075
EudraCT Identifier:
N/A
EU CT ID:
N/A
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Other

Study Details

Medical Condition
  • Unmapped
Study Drug
  • Biological: ENB-0040
Date
Jul 2009 - Dec 2014
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 5 - 12 Years
Requirements Information
Sex
Female & Male
Age
5 - 12 Years

Study Details

Medical Condition
  • Unmapped
Study Drug
  • Biological: ENB-0040
Date
Jul 2009 - Dec 2014
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 5 - 12 Years years
Requirements Information

Protocol Summary

This Clinical Trial is being conducted to study Hypophosphatasia (HPP), a bone disorder caused by gene mutations or changes. These gene mutations cause low levels of an enzyme needed to harden bone. The purpose of this study is to test the safety of the study drug called ENB-0040 and see what effects is has on human juveniles and HPP.

Trial Locations

No locations found.